Trevi Therapeutics (NASDAQ:TRVI) Upgraded at Leerink Partnrs

Leerink Partnrs upgraded shares of Trevi Therapeutics (NASDAQ:TRVI) to a strong-buy rating in a research report report published on Monday, Zacks.com reports. Leerink Partnrs also issued estimates for Trevi Therapeutics’ Q3 2024 earnings at ($0.12) EPS, Q4 2024 earnings at ($0.11) EPS, FY2024 earnings at ($0.46) EPS, Q1 2025 earnings at ($0.11) EPS, Q2 2025 earnings at ($0.11) EPS, Q3 2025 earnings at ($0.12) EPS, Q4 2025 earnings at ($0.10) EPS, FY2025 earnings at ($0.44) EPS and FY2026 earnings at ($0.45) EPS.

Other equities analysts also recently issued research reports about the stock. EF Hutton Acquisition Co. I raised shares of Trevi Therapeutics to a strong-buy rating in a research note on Monday, August 19th. Leerink Partners initiated coverage on Trevi Therapeutics in a research note on Monday. They issued an outperform rating and a $7.00 price objective on the stock. Raymond James started coverage on Trevi Therapeutics in a research note on Friday, August 30th. They set an outperform rating and a $9.00 target price for the company. Rodman & Renshaw initiated coverage on Trevi Therapeutics in a research note on Thursday, June 13th. They issued a buy rating and a $7.00 price target on the stock. Finally, HC Wainwright started coverage on shares of Trevi Therapeutics in a research report on Friday, August 30th. They set a buy rating and a $6.00 price objective for the company. Six analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of Buy and a consensus price target of $7.67.

Trevi Therapeutics Trading Up 4.8 %

Shares of TRVI stock opened at $3.30 on Monday. Trevi Therapeutics has a 1-year low of $0.97 and a 1-year high of $4.00. The stock has a market cap of $239.55 million, a price-to-earnings ratio of -9.71 and a beta of 0.96. The stock has a 50-day moving average of $2.89 and a 200-day moving average of $2.88.

Trevi Therapeutics (NASDAQ:TRVI) last released its earnings results on Thursday, August 8th. The company reported ($0.12) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.01). During the same quarter last year, the business earned ($0.07) EPS. Sell-side analysts forecast that Trevi Therapeutics will post -0.47 earnings per share for the current year.

Insider Buying and Selling

In other Trevi Therapeutics news, insider Thomas Sciascia sold 18,660 shares of the business’s stock in a transaction on Friday, August 16th. The shares were sold at an average price of $2.76, for a total transaction of $51,501.60. Following the completion of the sale, the insider now owns 220,315 shares in the company, valued at approximately $608,069.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, insider Thomas Sciascia sold 18,660 shares of Trevi Therapeutics stock in a transaction that occurred on Friday, August 16th. The stock was sold at an average price of $2.76, for a total transaction of $51,501.60. Following the transaction, the insider now owns 220,315 shares of the company’s stock, valued at $608,069.40. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Jennifer L. Good sold 10,981 shares of the stock in a transaction on Wednesday, September 4th. The shares were sold at an average price of $3.02, for a total value of $33,162.62. Following the completion of the sale, the chief executive officer now directly owns 213,313 shares of the company’s stock, valued at $644,205.26. The disclosure for this sale can be found here. Insiders have sold a total of 40,355 shares of company stock worth $116,663 in the last ninety days. Corporate insiders own 24.37% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. The Manufacturers Life Insurance Company lifted its holdings in Trevi Therapeutics by 87.6% during the second quarter. The Manufacturers Life Insurance Company now owns 24,524 shares of the company’s stock worth $73,000 after acquiring an additional 11,450 shares during the period. Logos Global Management LP boosted its stake in Trevi Therapeutics by 27.3% in the second quarter. Logos Global Management LP now owns 2,800,000 shares of the company’s stock valued at $8,344,000 after acquiring an additional 600,000 shares during the last quarter. Ally Bridge Group NY LLC bought a new position in shares of Trevi Therapeutics during the 2nd quarter valued at approximately $4,395,000. Hsbc Holdings PLC bought a new stake in shares of Trevi Therapeutics in the 2nd quarter worth approximately $61,000. Finally, Dimensional Fund Advisors LP lifted its stake in Trevi Therapeutics by 217.6% in the second quarter. Dimensional Fund Advisors LP now owns 72,210 shares of the company’s stock valued at $215,000 after purchasing an additional 49,475 shares during the last quarter. 95.76% of the stock is currently owned by hedge funds and other institutional investors.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.